H

Haloperidol

Ability to drive, haloperidol [2] ---> SmPC of [2] of eMC

Some degree of sedation or impairment of alertness may occur, particularly with higher doses and at the start of treatment, and may be potentiated by alcohol or other CNS depressants.

Abiraterone [1], haloperidol ---> SmPC of [1] of EMA

Caution is advised when administering abiraterone with medicinal products activated by or metabolised by CYP2D6, particularly with medicinal products that have a narrow therapeutic index.

Adrenaline, haloperidol [2] ---> SmPC of [2] of eMC

Haloperidol may antagonise the action of adrenaline

Alcohol, haloperidol

The concomitant use may enhance the alcohol effect and decrease the blood pressure

Alprazolam, haloperidol [2] ---> SmPC of [2] of eMC

Inhibition of the CYP3A4 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Amantadine, haloperidol

The co-administration of amantadine with drugs that prolong the QT interval is contraindicated

Amiodarone [1], haloperidol ---> SmPC of [1] of eMC

The combined therapy of amiodarone with drugs which prolong the QT interval is contra-indicated due to the increased risk of torsades de pointes

Amisulpride, haloperidol

Concomitant use of amisulpride with haloperidol is not recommended

Amitriptyline [1], haloperidol ---> SmPC of [1] of eMC

Concomitant use of haloperidol with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended

Amphetamine, haloperidol ---> SmPC of [lisdexamfetamine] of eMC

Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amfetamines.

Antiadrenergics, haloperidol [2] ---> SmPC of [2] of eMC

Haloperidol may reverse the blood-pressure-lowering effects of adrenergic-blocking agents

Anticholinergics, haloperidol

The co-administration may enhance the anticholinergic effect

Anticoagulants, haloperidol

It is recommended the regular control of coagulation status

Antihypertensives, haloperidol

The co-administration may enhance the hypotensive effect

Atropine, haloperidol

The co-administration may enhance the anticholinergic effect

Azithromycin, haloperidol

The concomitant use may increase the risk of cardiac arrhythmia.

Biperiden, haloperidol

The co-administration may enhance the anticholinergic effect

Bosutinib [1], haloperidol ---> SmPC of [1] of EMA

Bosutinib should be used with caution in patients who have or may develop prolongation of QT, including those patients taking anti-arrhythmic medicinal products or other medicinal products that may lead to QT prolongation

Breast-feeding, haloperidol [2] ---> SmPC of [2] of eMC

Haloperidol is excreted in breast milk. There have been isolated cases of extrapyramidal symptoms in breast-fed children. If the use of haloperidol is essential, the benefits of breast feeding should be balanced against its potential risks

Bretylium, haloperidol [2] ---> SmPC of [2] of eMC

Budipine, haloperidol

The co-administration of budipine with drugs known to prolong QT interval is contraindicated

Buspirone [1], haloperidol ---> SmPC of [1] of eMC

Concomitant administration of haloperidol and buspirone can increase haloperidol serum levels.

Capreomycin, haloperidol

The respiratory depression caused by the polypeptide antibiotic may be enhanced by haloperidol

Carbamazepine, haloperidol [2] ---> SmPC of [2] of eMC

When prolonged treatment with enzyme-inducing drugs is added to haloperidol therapy, this results in a significant reduction of haloperidol plasma levels.

Carteolol, haloperidol

The co-administration increases the risk of heart rhythm disorders, particularly torsades de pointes

Carvedilol [1], haloperidol ---> SmPC of [1] of eMC

The enzymatic inhibition may increase the plasma levels of carvedilol

Ceritinib [1], haloperidol ---> SmPC of [1] of EMA

Ceritinib should be used with caution in patients taking other medicinal products that may lead to QT prolongation. Monitoring of the QT interval is indicated in the event of combinations of such medicinal products

Chlorpromazine, haloperidol [2] ---> SmPC of [2] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Cimetidine, haloperidol

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Cisapride, haloperidol

The co-administration of cisapride with drugs that may prolong the QT interval and/or induce torsades de pointes is contraindicated

Citalopram [1], haloperidol ---> SmPC of [1] of eMC

Co-administration of citalopram with medicinal products that prolong the QT interval is contraindicated

Class IA antiarrhythmic agents, haloperidol [2] ---> SmPC of [2] of eMC

Class III antiarrhythmic agents, haloperidol [2] ---> SmPC of [2] of eMC

Clonidine, haloperidol

High intravenous doses of clonidine enhance the arrhytmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol

CNS depressants, haloperidol [2] ---> SmPC of [2] of eMC

In common with all neuroleptics, haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs.

Coffee, haloperidol

The concomitant intake of haloperidol and coffee or tea may decrease the effect of haloperidol

Colistin, haloperidol

The respiratory depression caused by the polypeptide antibiotic may be enhanced by haloperidol

Dabrafenib [1], haloperidol ---> SmPC of [1] of EMA

Interactions with many medicinal products eliminated through metabolism or active transport is expected. These medicinal products are to be avoided or used with caution.

Delamanid [1], haloperidol ---> SmPC of [1] of EMA

Treatment with delamanid should not be initiated in patients with risk factors like taking medicinal products that are known to prolong the QTc interval, unless the possible benefit is considered to outweigh the potential risks.

Dextromethorphan, haloperidol

The CYP2D6 inhibition may increase the plasma concentrations of dextromethorphan

Dextromethorphan/quinidine [1], haloperidol ---> SmPC of [1] of EMA

Concomitant use of dextromethorphan/quinidine and haloperidol, CYP2D6 substrate that also prolongs QT interval, requires caution

Disopyramide, haloperidol [2] ---> SmPC of [2] of eMC

Disulfiram, haloperidol

Possible decreased effect of disulfiram

Dofetilide, haloperidol [2] ---> SmPC of [2] of eMC

Dopamine agonists, haloperidol

The co-administration of haloperidol with dopamine agonists may weaken the effects of the dopamine agonists

Dopamine antagonists, haloperidol

The co-administration of haloperidol and dopamine antagonists may enhance the extrapyramidal motor effects

Dopamine [1], haloperidol ---> SmPC of [1] of eMC

Dopamine induced renal and mesenteric vasodilation is antagonised by haloperidol or other butyrophenones

Droperidol [1], haloperidol ---> SmPC of [1] of eMC

Medicinal products known to prolong the QTc interval should not be concomitantly administered with droperidol.

Electrolyte imbalance, haloperidol [2] ---> SmPC of [2] of eMC

Concurrent use of drugs causing electrolyte imbalance may increase the risk of ventricular arrhythmias and is not recommended. Diuretics, in particular those causing hypokalaemia, should be avoided

Enzalutamide [1], haloperidol ---> SmPC of [1] of EMA

Enzalutamide, enzymatic inductor, may increase the metabolism of haloperidol and decrease its plasma levels and effect

Enzyme inductors, haloperidol [2] ---> SmPC of [2] of eMC

When prolonged treatment with enzyme-inducing drugs is added to haloperidol therapy, this results in a significant reduction of haloperidol plasma levels.

Escitalopram [1], haloperidol ---> SmPC of [1] of eMC

Co-administration of escitalopram with medicinal products that prolong the QT-interval is contraindicated.

Fluoxetine [1], haloperidol ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Fluvoxamine, haloperidol [2] ---> SmPC of [2] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Glycerol phenylbutyrate [1], haloperidol ---> SmPC of [1] of EMA

Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in urea cycle disorders (UCDs) patients.

Gonadorelin, haloperidol

Haloperidol decreases the reaction to gonadorelin due to haloperidol may increase the prolactin

Guanethidine, haloperidol [2] ---> SmPC of [2] of eMC

Haloperidol may reverse the blood-pressure-lowering effects of adrenergic-blocking agents

Haloperidol [1], hypnotics ---> SmPC of [1] of eMC

In common with all neuroleptics, haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs.

Haloperidol [1], hypokalemia ---> SmPC of [1] of eMC

Concurrent use of drugs causing electrolyte imbalance may increase the risk of ventricular arrhythmias and is not recommended. Diuretics, in particular those causing hypokalaemia, should be avoided

Haloperidol [1], itraconazol ---> SmPC of [1] of eMC

Inhibition of the CYP3A4 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], levodopa ---> SmPC of [1] of eMC

Haloperidol may impair the antiparkinson effects of levodopa.

Haloperidol [1], macrolide antibiotics ---> SmPC of [1] of eMC

Haloperidol [1], maprotiline ---> SmPC of [1] of eMC

Haloperidol [1], mefloquine ---> SmPC of [1] of eMC

Haloperidol [1], methyldopa ---> SmPC of [1] of eMC

An enhanced CNS effect, when haloperidol combined with methyldopa, has also been reported.

Haloperidol [1], nefazodone ---> SmPC of [1] of eMC

Inhibition of the CYP3A4 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], paroxetine ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], phenindione ---> SmPC of [1] of eMC

Antagonism of the effect of the anticoagulant phenindione has been reported.

Haloperidol [1], phenobarbital ---> SmPC of [1] of eMC

When prolonged treatment with enzyme-inducing drugs is added to haloperidol therapy, this results in a significant reduction of haloperidol plasma levels.

Haloperidol [1], phenytoin ---> SmPC of [1] of eMC

When prolonged treatment with enzyme-inducing drugs is added to haloperidol therapy, this results in a significant reduction of haloperidol plasma levels.

Haloperidol [1], pimozide ---> SmPC of [1] of eMC

Haloperidol [1], pregnancy ---> SmPC of [1] of eMC

Haloperidol should be used during pregnancy only if the anticipated benefit outweighs the risk and the administered dose and duration of treatment should be as low and as short as possible.

Haloperidol [1], procainamide ---> SmPC of [1] of eMC

Haloperidol [1], promethazine ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], QT interval prolonging drugs ---> SmPC of [1] of eMC

Haloperidol [1], quinidine ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], quinine ---> SmPC of [1] of eMC

Haloperidol [1], rifampicin ---> SmPC of [1] of eMC

When prolonged treatment with enzyme-inducing drugs is added to haloperidol therapy, this results in a significant reduction of haloperidol plasma levels.

Haloperidol [1], sedatives ---> SmPC of [1] of eMC

In common with all neuroleptics, haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs.

Haloperidol [1], sertindole ---> SmPC of [1] of eMC

Haloperidol [1], sertraline ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], sotalol ---> SmPC of [1] of eMC

Haloperidol [1], strong analgesics ---> SmPC of [1] of eMC

In common with all neuroleptics, haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs.

Haloperidol [1], strong CYP2D6 inhibitors ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], strong CYP3A4 inhibitors ---> SmPC of [1] of eMC

Inhibition of the CYP3A4 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol [1], sympathomimetics ---> SmPC of [1] of eMC

Haloperidol may antagonise the action of sympathomimetic agents

Haloperidol [1], terfenadine ---> SmPC of [1] of eMC

Haloperidol [1], tricyclic antidepressant ---> SmPC of [1] of eMC

Haloperidol is an inhibitor of CYP 2D6. Haldol inhibits the metabolism of tricyclic antidepressants, thereby increasing plasma levels of these drugs.

Haloperidol [1], venlafaxine ---> SmPC of [1] of eMC

Inhibition of the CYP2D6 by another drug may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.

Haloperidol, hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Haloperidol, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Haloperidol, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Haloperidol, ibutilide

Possible increase of proarrhythmic risk if ibutilide is used with drugs that prolong the QT interval. Contraindicated within 4 hours after completing infusion

Haloperidol, indapamide [2] ---> SmPC of [2] of eMC

The co-administration may increase the risk of ventricular arrhythmias, particularly torsades de pointes (hypokalemia is a risk factor)

Haloperidol, indocyanine green

Extinction attenuation

Haloperidol, indometacin

Increased adverse effects on CNS, such as somnolence and states of confusion

Haloperidol, interferon

Caution should be used when administering interferon with medicines mainly metabolised by hepatic cytochrome P450 and have a narrow therapeutic window

Haloperidol, isoniazid

Mutual potentiation of effects. Relevant increase of plasma levels of haloperidol

Haloperidol, ketoconazole [2] ---> SmPC of [2] of EMA

Potential increased in plasma concentrations of haloperidol. Not recommended due to the increased risk of QT prolongation and extrapyramidal symptoms. It may be necessary to reduce haloperidol dosage.

Haloperidol, levacetylmethadol [2] ---> SmPC of [2] of EMA

The co-administration of levacetylmethadol with medicinal products that prolong the interval QT is contraindicated

Haloperidol, levomepromazine [2] ---> SmPC of [2] of eMC

There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval

Haloperidol, lisdexamfetamine [2] ---> SmPC of [2] of eMC

Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amfetamines.

Haloperidol, lisuride

Dopamine antagonists may decrease the effect of lisuride. Co-administration is not recommended

Haloperidol, lithium

In rare cases, an encephalopathy-like syndrome has been reported in combination with lithium and haloperidol.

Haloperidol, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with torsades de pointes-inducing medicinal products

Haloperidol, metoclopramide

The co-administration of haloperidol and dopamine antagonists may enhance the extrapyramidal motor effects

Haloperidol, moxifloxacin [2] ---> SmPC of [2] of eMC

The co-administration may have an additive effect on the QT interval prolongation. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. The combination is contraindicated.

Haloperidol, naltrexone/bupropion [2] ---> SmPC of [2] of EMA

Co-administration of bupropion with drugs that are metabolised by CYP2D6 isozyme should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medicinal product.

Haloperidol, neuroleptics

The co-administration of haloperidol and dopamine antagonists may enhance the extrapyramidal motor effects

Haloperidol, nilotinib [2] ---> SmPC of [2] of EMA

Significant prolongation of the QT interval may occur when nilotinib is inappropriately taken with medicinal products with a known potential to prolong QT. Prolongation of the QT interval may expose patients to the risk of fatal outcome.

Haloperidol, pasireotide [2] ---> SmPC of [2] of EMA

Pasireotide should be used with caution in patients who are concomitantly receiving medicinal products that prolong the QT interval

Haloperidol, phenothiazines [2] ---> SmPC of [2] of eMC

Haloperidol, piperaquine/artenimol [2] ---> SmPC of [2] of EMA

The combination of piperaquine/dihydroartemisinin with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval

Haloperidol, pixantrone [2] ---> SmPC of [2] of EMA

Haloperidol is metabolised by CYP1A2, and therefore, a theoretical concern exists that co-administration of pixantrone may increase blood levels of this medicinal product.

Haloperidol, polymyxin

The respiratory depression caused by the polypeptide antibiotic may be enhanced by haloperidol

Haloperidol, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by haloperidol

Haloperidol, promazine [2] ---> SmPC of [2] of eMC

Concomitant use of promazine with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore, concomitant use of these products is not recommended.

Haloperidol, protirelin

Enhancement of TSH-increase

Haloperidol, quetiapine [2] ---> SmPC of [2] of eMC

The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antipsychotics risperidone or haloperidol.

Haloperidol, ranolazine

The CYP2D6 inhibition may increase the plasma concentrations of haloperidol

Haloperidol, ribociclib [2] ---> SmPC of [2] of EMA

Co-administration of Kisqali with medicinal products with a known potential to prolong the QT interval such as anti-arrhythmic medicinal products should be avoided

Haloperidol, ritonavir [2] ---> SmPC of [2] of EMA

Ritonavir, CYP2D6 inhibitor, may increase the concentrations of haloperidol. Careful monitoring of therapeutic and adverse effects is recommended

Haloperidol, rivastigmine [2] ---> SmPC of [2] of EMA

Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of rivastigmine with torsades de pointes-inducing medicinal products should be observed with caution and clinical monitoring (ECG) may also be required.

Haloperidol, saquinavir/ritonavir ---> SmPC of [saquinavir] of EMA

The combination is contraindicated due to the potential for life threatening cardiac arrhythmia

Haloperidol, sodium phenylbutyrate [2] ---> SmPC of [2] of EMA

There have been published reports of hyperammonaemia being induced by haloperidol and by valproate.

Haloperidol, sparfloxacin [2] ---> SmPC of [2] of eMC

Haloperidol, stiripentol [2] ---> SmPC of [2] of EMA

Stiripentol is an inhibitor of the enzymes CYP2D6 and may markedly increase the plasma concentrations of substances metabolised by these enzymes and increase the risk of adverse reactions

Haloperidol, sulpiride [2] ---> SmPC of [2] of eMC

Combination of sulpiride with drugs which could induce torsades de pointes or prolong the QT interval is not recommended

Haloperidol, sun

Patients should be advised to minimise exposure to sunlight during therapy, as haloperidol may potentially have a photosensitizing effect.

Haloperidol, tea

The concomitant intake of haloperidol and coffee or tea may decrease the effect of haloperidol

Haloperidol, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended when MicardisPlus is administered with drugs affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics) and torsades de pointes inducing medicinal products

Haloperidol, tetrabenazine

The co-administration may cause significant dopamine depletion

Haloperidol, tiapride

Tiapride should not be combined with drugs that prolong the QT interval. These drugs (with the exception of anti-infectious) should be discontinued, if possible, if they induce torsades de pointes

Haloperidol, tolterodine

The co-administration may increase the plasma concentrations of tolterodine

Haloperidol, toremifene [2] ---> SmPC of [2] of EMA

An additive effect on QT interval prolongation between toremifene and medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias. Co-administration is contraindicated

Haloperidol, trazodone [2] ---> SmPC of [2] of eMC

Concomitant use of trazodone with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Caution should be used when these drugs are coadministered with trazodone.

Haloperidol, vandetanib [2] ---> SmPC of [2] of EMA

The concomitant use of vandetanib with medicinal products known to also prolong the QTc interval and/or induce Torsades de pointes is either contraindicated or not recommended

Haloperidol, xipamide

The combination increases the risk of ventricular arrhythmias, particularly torsades de pointes (favored by hypokaliemia). It is recommended a special caution

CONTRAINDICATIONS of Haloperidol

- Comatose states,

- CNS depression,

- Parkinson's disease,

- known hypersensitivity to haloperidol,

- lesions of basal ganglia.

- In common with other neuroleptics, haloperidol has the potential to cause rare prolongation of the QT interval. Use of haloperidol is therefore contra-indicated in patients with clinically significant cardiac disorders e.g. recent acute myocardial infarction, uncompensated heart failure, arrhythmias treated with class IA and III antiarrhythmic medicinal products, QTc interval prolongation, history of ventricular arrhythmia or torsades de pointes clinically significant bradycardia, second or third degree heart block and uncorrected hypokalaemia. Haloperidol should not be used concomitantly with other QT prolonging drugs

http://www.medicines.org.uk/emc/

Helicobacter Test (Pylobactell)

Antibiotics, Helicobacter Test [2] ---> SmPC of [2] of EMA

The test must not be used until four weeks without systemic antibacterial therapy and two weeks after last dose of acid antisecretory agents. This is especially important after eradication therapy.

Antibiotics, Helicobacter Test [2] ---> SmPC of [2] of EMA

The validity of the test result may be affected if the patient is currently being treated with antibiotics or a proton-pump inhibitor or has completed a course of treatment with these drugs.

Breast-feeding [1], Helicobacter Test ---> SmPC of [1] of EMA

The endogenous production of urea amounts to 25 - 35 g/day. It is therefore unlikely that the dose of 100 mg urea should cause any adverse effect on pregnancy and lactation.

Helicobacter Test [1], pregnancy ---> SmPC of [1] of EMA

The endogenous production of urea amounts to 25 - 35 g/day. It is therefore unlikely that the dose of 100 mg urea should cause any adverse effect on pregnancy and lactation.

Helicobacter Test [1], proton pump inhibitors ---> SmPC of [1] of EMA

The validity of the test result may be affected if the patient is currently being treated with antibiotics or a proton-pump inhibitor or has completed a course of treatment with these drugs.

Helicobacter Test [1], urease activity ---> SmPC of [1] of EMA

The results may be affected in general by all treatments interfering with H.pylori status or urease activity.

CONTRAINDICATIONS of Helicobacter Test (Pylobactell)

- The test must not be used in patients with documented or suspected gastric infection or atrophic gastritis, which might interfere with the urea breath test

https://www.ema.europa.eu/en/documents/product-information/pylobactell-epar-product-information_en.pdf 04/12/2023

Hemine

Barbiturates, hemine [2] ---> SmPC of [2] of eMC

The metabolism of concomitantly administered drugs that are metabolised by cytochrome P450 enzymes may increase during administration of hemin, leading to lower systemic exposure.

Breast-feeding, hemine [2] ---> SmPC of [2] of eMC

Due to limited data the use of hemin cannot be recommended unless clearly necessary during breast-feeding.

Drugs primarily metabolised by CYP, hemine [2] ---> SmPC of [2] of eMC

The metabolism of concomitantly administered drugs that are metabolised by cytochrome P450 enzymes may increase during administration of hemin, leading to lower systemic exposure.

Estrogens, hemine [2] ---> SmPC of [2] of eMC

The metabolism of concomitantly administered drugs that are metabolised by cytochrome P450 enzymes may increase during administration of hemin, leading to lower systemic exposure.

Hemine [1], pregnancy ---> SmPC of [1] of eMC

Due to limited data the use of hemin cannot be recommended unless clearly necessary during pregnancy

Hemine [1], steroids ---> SmPC of [1] of eMC

The metabolism of concomitantly administered drugs that are metabolised by cytochrome P450 enzymes may increase during administration of hemin, leading to lower systemic exposure.

CONTRAINDICATIONS of Hemine

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

http://www.medicines.org.uk/emc/

Herpes zoster vaccine (live) (Zostavax)

Breast-feeding, herpes zoster vaccine (live) [2] ---> SmPC of [2] of EMA

A decision must be made whether to discontinue breast-feeding or to not administer ZOSTAVAX taking into account the benefit of breast feeding for the child and the benefit of vaccination for the woman.

Corticosteroids, herpes zoster vaccine (live) [2] ---> SmPC of [2] of EMA

ZOSTAVAX is not contraindicated for use in individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or in patients who are receiving corticosteroids as replacement therapy, e.g., for adrenal insufficiency

Fertility, herpes zoster vaccine (live) [2] ---> SmPC of [2] of EMA

ZOSTAVAX has not been evaluated in fertility studies.

Herpes zoster vaccine (live) [1], immunosuppressives ---> SmPC of [1] of EMA

Herpes zoster vaccine (live) [1], influenza vaccine ---> SmPC of [1] of EMA

ZOSTAVAX can be administered concomitantly with inactivated influenza vaccine as separate injections and at different body sites (see section 5.1).

Herpes zoster vaccine (live) [1], pneumococcal vaccine ---> SmPC of [1] of EMA

The concomitant use of ZOSTAVAX and a 23-valent pneumococcal polysaccharide vaccine resulted in reduced immunogenicity of ZOSTAVAX in a small clinical trial.

Herpes zoster vaccine (live) [1], pneumococcal vaccine ---> SmPC of [1] of EMA

However, data collected in a large observational study did not indicate increased risk for developing herpes zoster after concomitant administration of the two vaccines.

Herpes zoster vaccine (live) [1], pregnancy ---> SmPC of [1] of EMA

ZOSTAVAX is not recommended to be administered to pregnant women. In any case, pregnancy should be avoided for one month following vaccination (see section 4.3).

Herpes zoster vaccine (live) [1], vaccinations ---> SmPC of [1] of EMA

No data are currently available regarding concomitant use with other vaccines.

CONTRAINDICATIONS of Herpes zoster vaccine (live) (Zostavax)

- Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or neomycin (which may be present as trace residues, see sections 2 and 4.4).

- Primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukaemias; lymphoma; other conditions affecting the bone marrow or lymphatic system; immunosuppression due to HIV/AIDS (see sections 4.4, 4.8 and 5.1); cellular immune deficiencies.

- Immunosuppressive therapy (including high-dose corticosteroids) (see sections 4.4 and 4.8); however, ZOSTAVAX is not contraindicated for use in individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or in patients who are receiving corticosteroids as replacement therapy, e.g., for adrenal insufficiency (see sections 4.8 and 5.1).

- Active untreated tuberculosis.

- Pregnancy. Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6).

https://www.ema.europa.eu/en/documents/product-information/zostavax-epar-product-information_en.pdf 11/06/2025 (withdrawn)

Other trade names: Shingrix,

Human hepatitis B immunoglobulin (Zutectra)

Breast-feeding, human hepatitis B immunoglobulin [2] ---> SmPC of [2] of EMA

The safety of this medicinal product for use in breast-feeding has not been established in controlled clinical trials and therefore should only be given with caution to breast-feeding mothers.

Fertility, human hepatitis B immunoglobulin [2] ---> SmPC of [2] of EMA

No fertility studies have been performed (see section 5.3).

Human hepatitis B immunoglobulin [1], pregnancy ---> SmPC of [1] of EMA

The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women.

Human hepatitis B immunoglobulin [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines such as rubella, mumps, measles and varicella for a period of 3 months.

Human hepatitis B immunoglobulin [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

After administration of this medicinal product, an interval of at least 3 months should elapse before vaccination with live attenuated virus vaccines.

Human hepatitis B immunoglobulin [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

Human hepatitis B immunoglobulin should be administrated three to four weeks after vaccination with such a live attenuated vaccine

CONTRAINDICATIONS of Human hepatitis B immunoglobulin (Zutectra)

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to human immunoglobulins. In particular, in very rare cases of IgA deficiency when the patient to be treated has antibodies against IgA.

- Zutectra must not be administered intravascularly.

https://www.ema.europa.eu/en/documents/product-information/zutectra-epar-product-information_en.pdf 15/10/2025

Other trade names: ImmunoGam,

Hepatitis B immunoglobulin

Breast-feeding, hepatitis B immunoglobulin [2] ---> SmPC of [2] of EMA

Immunoglobulins are excreted into milk but no harmful effects on the neonate are to be expected.

Hepatitis B immunoglobulin [1], measles vaccine ---> SmPC of [1] of EMA

Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines for a period of 3 months

Hepatitis B immunoglobulin [1], mumps vaccine ---> SmPC of [1] of EMA

Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines for a period of 3 months

Hepatitis B immunoglobulin [1], pregnancy ---> SmPC of [1] of EMA

Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the fetus and the neonate are to be expected.

Hepatitis B immunoglobulin [1], rubella vaccine ---> SmPC of [1] of EMA

Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines for a period of 3 months

Hepatitis B immunoglobulin [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines for a period of 3 months

Hepatitis B immunoglobulin [1], varicella vaccine ---> SmPC of [1] of EMA

Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines for a period of 3 months

CONTRAINDICATIONS of Hepatitis B immunoglobulin

- Hypersensitivity to any of the components.

- Hypersensitivity to human immunoglobulins, especially in very rare cases of IgA deficiency when the patient has antibodies against IgA.

http://www.ema.europa.eu/

Hepatitis b vaccine (Heplisav)

Ability to drive, hepatitis B vaccine [2] ---> SmPC of [2] of EMA

HEPLISAV B may have a moderate influence on the ability to drive and use machine. Some of the effects mentioned under Section 4.8 "Undesirable Effects" (e.g., malaise) may affect the ability to drive or operate machinery.

Breast-feeding, hepatitis B vaccine [2] ---> SmPC of [2] of EMA

A decision must be made whether to discontinue breast-feeding or to abstain from HEPLISAV B vaccination taking into account the benefit of breast-feeding for the child and the benefit of vaccination for the woman.

Fertility, hepatitis B vaccine [2] ---> SmPC of [2] of EMA

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity

Hepatitis B immunoglobulin [1], hepatitis B vaccine ---> SmPC of [1] of EMA

En circumstances where HEPLISAV B is administered with a standard dose of hepatitis B immunoglobulin (HBIG), these should be given at separate injection sites.

Hepatitis B vaccine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of HEPLISAV B during pregnancy. Vaccination during pregnancy should only be performed if the risk-benefit ratio at the individual level outweighs possible risks for the foetus.

Hepatitis B vaccine [1], vaccinations ---> SmPC of [1] of EMA

As there are no data on co-administration of HEPLISAV B with other vaccines, the concomitant use of HEPLISAV B with other vaccines is not recommended.

CONTRAINDICATIONS of Hepatitis b vaccine (Heplisav)

- Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1.

- Severe allergic reaction, such as anaphylaxis, after a previous dose of any hepatitis B vaccine.

- Hypersensitivity to yeast.

https://www.ema.europa.eu/en/documents/product-information/heplisav-b-epar-product-information_en.pdf 28/01/2026

Histamine dihydrochloride (Ceplene)

Ability to drive, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Administration of Ceplene can cause hypotension and may result in dizziness, light-headedness and blurred vision. Patients should not drive or operate machines for at least 1 hour after receiving Ceplene.

Antihistamines, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

H1 receptor blocking antihistamines or neuroleptics (anti-psychotics) with H1 receptor blocking properties that might decrease efficacy of histamine dihydrochloride should be avoided.

Antihypertensives, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Anti-hypertensive agents should be used with caution during treatment with histamine dihydrochloride. They may increase the toxicity of histamine dihydrochloride

Antimalarial agents, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Monoamine oxidase inhibitors, anti-malarial, and anti-trypanosomal active substances may alter the metabolism of histamine dihydrochloride and should be avoided

Betablockers, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Beta-blockers should be used with caution during treatment with histamine. They may increase the toxicity of histamine

Breast-feeding, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Ceplene in conjunction with IL-2 must not be used during breast-feeding.

Cimetidine, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

H2 receptor antagonists with imidazole structures similar to histamine must not be used during treatment with histamine dihydrochloride

Clonidine, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

H2 receptor antagonists with imidazole structures similar to histamine must not be used during treatment with histamine dihydrochloride

Corticosteroids, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Systemic steroid must not be used during treatment with histamine dihydrochloride

Fertility, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

No clinical data are available on the effects of Ceplene on fertility. Animal studies revealed no adverse effects on fertility apart from a slight reduction in implantations and viable foetuses (see section 5.3).

H2 antagonists, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

H2 receptor antagonists with imidazole structures similar to histamine must not be used during treatment with histamine dihydrochloride

Histamine dihydrochloride [1], IMAOs ---> SmPC of [1] of EMA

Monoamine oxidase inhibitors, anti-malarial, and anti-trypanosomal active substances may alter the metabolism of histamine dihydrochloride and should be avoided

Histamine dihydrochloride [1], medicines with cardiotoxic effects ---> SmPC of [1] of EMA

Concurrent administration of medicinal products with cardiotoxicity or blood pressure lowering effects may increase the toxicity of Ceplene.

Histamine dihydrochloride [1], muscle relaxants ---> SmPC of [1] of EMA

It has been noted that neuromuscular blocking agents, narcotic analgesics, and various contrast media can induce the release of endogenous histamine; therefore the additive effect should be considered

Histamine dihydrochloride [1], opioid analgesics ---> SmPC of [1] of EMA

Histamine dihydrochloride [1], pregnancy ---> SmPC of [1] of EMA

Ceplene in conjunction with IL-2 must not be used during pregnancy.

Histamine dihydrochloride [1], steroids ---> SmPC of [1] of EMA

H2 receptor antagonists with imidazole structures similar to histamine must not be used during treatment with histamine dihydrochloride

Histamine dihydrochloride [1], tricyclic antidepressant ---> SmPC of [1] of EMA

Tricyclic anti-depressants may have H1 and H2 receptor blocking properties and should be avoided.

Histamine dihydrochloride [1], women of childbearing potential ---> SmPC of [1] of EMA

Women of childbearing potential and sexually active men must use effective methods of contraception during treatment with Ceplene and IL-2.

CONTRAINDICATIONS of Histamine dihydrochloride (Ceplene)

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Patients with significantly compromised cardiac function, e.g., NYHA Class III/IV.

- Patients receiving systemic steroid therapy, clonidine and H2 blocking agents.

- Patients who have received an allogenic stem cell transplant.

- During pregnancy.

- During breast feeding.

https://www.ema.europa.eu/en/documents/product-information/ceplene-epar-product-information_en.pdf 19/04/2023

Histrelin

Breast-feeding, histrelin [2] ---> SmPC of [2] of eMC

Due to its indication, it has not been studied in pregnant or breast-feeding women and is not for use in women.

Histrelin [1], pregnancy ---> SmPC of [1] of eMC

Due to its indication, it has not been studied in pregnant or breast-feeding women and is not for use in women.

CONTRAINDICATIONS of Histrelin

Vantas is contraindicated in patients with hypersensitivity to histrelin or to any of the excipients listed in section 6.1, GnRH, GnRH-agonists/- analogues, or stearic acid.

Anaphylactic reactions to synthetic LHRH or LHRH-agonists/-analogues, have also been reported.

http://www.medicines.org.uk/emc/

Human normal immunoglobulin (Kiovig)

Ability to drive, human normal immunoglobulin [2] ---> SmPC of [2] of EMA

The ability to drive and operate machines may be impaired by some adverse reactions associated with KIOVIG.

Breast-feeding, human normal immunoglobulin [2] ---> SmPC of [2] of EMA

Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry. No negative effects on the breastfed newborn/infants are anticipated.

Fertility, human normal immunoglobulin [2] ---> SmPC of [2] of EMA

Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.

Glucose, human normal immunoglobulin [2] ---> SmPC of [2] of EMA

Dilution of KIOVIG with a 5% glucose solution may result in increased blood glucose levels

Human normal immunoglobulin [1], loop diuretics ---> SmPC of [1] of EMA

Avoidance of concomitant use of loop diuretics.

Human normal immunoglobulin [1], measles vaccine ---> SmPC of [1] of EMA

In the case of measles, this impairment may persist for up to 1 year. Therefore patients receiving measles vaccine should have their antibody status checked.

Human normal immunoglobulin [1], pregnancy ---> SmPC of [1] of EMA

Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.

Human normal immunoglobulin [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines.

Human normal immunoglobulin [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

Administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella.

Human normal immunoglobulin [1], varicella vaccine ---> SmPC of [1] of EMA

Vaccination should be deferred for at least 5 months

CONTRAINDICATIONS of Human normal immunoglobulin (Kiovig)

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA.

- Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgA containing product can result in anaphylaxis.

https://www.ema.europa.eu/en/documents/product-information/kiovig-epar-product-information_en.pdf 16/05/2025

Other trade names: Flebogamma DIF (previously Flebogammadif), Gammagard S/D, Hizentra, HyQvia, Igamplia, Intratect, Octagamocta, Plangamma, Privigen,

Hydralazine

Ability to drive, hydralazine

Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy

ACE inhibitors, hydralazine

The co-administration may increase the hypotensive effect

Acebutolol, hydralazine

The co-administration may increase the hypotensive effect

Alcohol, hydralazine [2] ---> SmPC of [2] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Alprenolol, hydralazine

The co-administration may increase the hypotensive effect

Amifostine, hydralazine

Concomitant use of hydralazine and amifostine can enhance the hypotensive effect. Concomitant use should be done 24 hours after interrupting the treatment with hydralazine

Amiodarone, hydralazine

The co-administration may increase the hypotensive effect

Antihypertensives, hydralazine

The co-administration may increase the hypotensive effect

Baclofen, hydralazine [2] ---> SmPC of [2] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Betablockers, hydralazine

Hydralazine may induce increased plasma levels of hepatically metabolised beta-blockers.

Bisoprolol [1], hydralazine ---> SmPC of [1] of eMC

The effect of bisoprolol can be potentiated by hydralazine

Breast-feeding, hydralazine [2] ---> SmPC of [2] of eMC

Hydralazine is excreted in breast milk. Mothers who are receiving hydralazine should not therefore breast feed their infants.

Bupranolol, hydralazine

The co-administration may increase the hypotensive effect

Calcium antagonists, hydralazine

The co-administration may increase the hypotensive effect

Carvedilol, hydralazine

Increased systemic availability of carvedilol

Cisplatin, hydralazine

The co-administration may intensify the nephrotoxic effects of cisplatin

Clonazepam, hydralazine

Enhanced hypotensive effect

Corticosteroids, hydralazine [2] ---> SmPC of [2] of eMC

Concurrent treatment of hydralazine may decrease the effects

Diazepam [1], hydralazine ---> SmPC of [1] of eMC

Enhanced hypotensive effect

Diazoxide, hydralazine [2] ---> SmPC of [2] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Diuretics, hydralazine

The co-administration may increase the hypotensive effect

Ephedrine, hydralazine

The co-administration may weaken the hypotensive effect

Esmolol, hydralazine

The co-administration may increase the hypotensive effect

Felodipine/metoprolol [1], hydralazine ---> SmPC of [1] of eMC

Enzyme inhibitors (hydralazine) may increase plasma concentrations of hepatically metabolised beta-blockers.

Hydralazine [1], IMAOs ---> SmPC of [1] of eMC

Concurrent treatment of hydralazine with MAOI's may decrease the effects

Hydralazine [1], muscle relaxants ---> SmPC of [1] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Hydralazine [1], NSAID ---> SmPC of [1] of eMC

Concurrent treatment of hydralazine may decrease the effects

Hydralazine [1], pentoxifylline ---> SmPC of [1] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Hydralazine [1], pregnancy ---> SmPC of [1] of eMC

Hydralazine crosses the placental barrier and is excreted in breast milk. Mothers who are receiving hydralazine should not therefore breast feed their infants.

Hydralazine [1], prostacyclin analogues ---> SmPC of [1] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Hydralazine, indometacin

The co-administration may weaken the hypotensive effect

Hydralazine, isoniazid

The co-administration may enhance the effect by competition for the degradation path

Hydralazine, labetalol

The co-administration may increase the bioavailability of labetalol

Hydralazine, lorazepam [2] ---> SmPC of [2] of eMC

Enhanced hypotensive effect

Hydralazine, methylphenidate

Concomitant use may decrease the antihypertensive effect

Hydralazine, metoprolol [2] ---> SmPC of [2] of eMC

Enzyme inhibitors (hydralazine) may increase plasma concentrations of hepatically metabolised beta-blockers.

Hydralazine, midazolam

Enhanced hypotensive effect

Hydralazine, nadolol

The co-administration may increase the hypotensive effect

Hydralazine, oxprenolol

Hydralazine may induce increased plasma levels of hepatically metabolised beta-blockers.

Hydralazine, perindopril

The co-administration may increase the hypotensive effect

Hydralazine, pindolol [2] ---> SmPC of [2] of eMC

Hydralazine may induce increased plasma levels of hepatically metabolised beta-blockers.

Hydralazine, pindolol/clopamide

Hydralazine may induce increased plasma level of beta-blockers.

Hydralazine, propranolol

Hydralazine may induce increased plasma levels of hepatically metabolised beta-blockers.

Hydralazine, pyridoxine

Hydralazine may increase the pyridoxine requirements

Hydralazine, quinidine

The co-administration may increase the hypotensive effect

Hydralazine, sodium selenite

The solution should not be mixed with reductants due to a precipitation of elemental selene cannot be excluded

Hydralazine, sotalol

The co-administration may increase the hypotensive effect

Hydralazine, sympathomimetics

The co-administration may weaken the hypotensive effect

Hydralazine, timolol [2] ---> SmPC of [2] of eMC

The bioavailability of timolol will be increased by co-administration with hydralazine

Hydralazine, tizanidine

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Hydralazine, triamterene [2] ---> SmPC of [2] of eMC

The co-administration of triamterene and hydralazine may enhance the hypotensive effect

Hydralazine, vasodilators

The co-administration may increase the hypotensive effect

CONTRAINDICATIONS of Hydralazine

- Hydralazine should not be given to patients with tachycardia and also in cases of left ventricular failure due to severe aortic or mitral stenosis or in constrictive pericarditis; in heart failure associated with high output (ie in thyrotoxicosis); isolated right ventricular failure due to pulmonary hypertension (ie cor pulmonale); hypersensitivity to hydralazine and dihydralazine or to any of the excipients. Idiopathic system lupus erythematosus (SLE) and related diseases. Dissecting aortic aneurism. Porphyria.

http://www.medicines.org.uk/emc/

Hydrochlorothiazide

Ability to drive, hydrochlorothiazide

Hydrochlorothiazid may cause dizziness, headache and vertigo

ACE inhibitors, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

ACTH, hydrochlorothiazide

Concomitant use of hydrochlorothiazide und amphotericin B (parenteral), carbenoxolone, corticosteroids, corticotropin (ACTH) or stimulant laxatives may intensify the electrolyte disorder, specially hypokaliemia

Acute angle-closure glaucoma, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma.

Adrenaline, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide may reduce the response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

AIIRA, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Alcohol, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Allopurinol, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Hydrochlorothiazid may increase the incidence of hypersensitivity reactions to allopurinol.

Amantadine, hydrochlorothiazide

The co-administration may reduce the clearance of amantadine, leading to higher plasma concentrations and toxic effects

Amiodarone, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Amisulpride, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Amphotericin, hydrochlorothiazide

Anaesthetics, hydrochlorothiazide

Increased hypotensive effect.

Anticholinergics, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents, apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.

Antigout preparations, hydrochlorothiazide

Possible increase of the level of serum uric acid. Dosage adjustment of the antigout medicinal product may be necessary

Antihypertensives, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Atropine, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents, apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.

Baclofen, hydrochlorothiazide

Increased antihypertensive effect

Barbiturates, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g.by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Bepridil, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Betablockers, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Biperiden, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents, apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.

Breast-feeding, hydrochlorothiazide

Hydrochlorothiazide is excreted in breast milk and should not be used during breastfeeding

Calcifediol, hydrochlorothiazide

The co-administration may decrease the calcium elimination and cause hypercalcemia

Calcium antagonists, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Calcium, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Administration of thiazide diuretics with vitamin D or with calcium salts may potentiate the rise in serum calcium.

Carbamazepine, hydrochlorothiazide ---> SmPC of [irbesartan/hydrochlorothiazide] of EMA

Concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatraemia.

Carbenoxolone, hydrochlorothiazide

Catecholamines, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide may reduce the response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

Celiprolol, hydrochlorothiazide

The co-administration may decrease the bioavailibility of celiprolol

Chlorpromazine, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Cholestyramine, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

The co-administration may decrease the absorption of hydrochlorothiazide. Hydrochlorothiazide should be administered 1 hour before or 4-6 hours after colestipol

Cisapride, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

It is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.

Class IA antiarrhythmic agents, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Class III antiarrhythmic agents, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Colestipol, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

The co-administration may decrease the absorption of hydrochlorothiazide. Hydrochlorothiazide should be administered 1 hour before or 4-6 hours after colestipol

Corticosteroids, hydrochlorothiazide

Coxibs, hydrochlorothiazide

NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics

Curare-type muscle relaxants, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazides potentiate the action of curare derivatives.

Cyamemazine, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Cyclophosphamide, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents and potentiate their myelosuppressive effects.

Cyclosporine, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant treatment of hydrochlorothiazide with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.

Cytotoxic agents, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents and potentiate their myelosuppressive effects.

Diazoxide, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.

Digital glycosides, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazide induced hypokalaemia/hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias. Periodic monitoring of serum potassium and ECG is recommended

Digoxin, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazide induced hypokalaemia/hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias. Periodic monitoring of serum potassium and ECG is recommended

Diphemanil, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Disopyramide, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Diuretics, hydrochlorothiazide

Increased hypotensive effect.

Dofetilide, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Epinephrine, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide may reduce the response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

Erythromycin, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Febuxostat [1], hydrochlorothiazide ---> SmPC of [1] of EMA

No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.

Felodipine [1], hydrochlorothiazide ---> SmPC of [1] of eMC

Hydrochlorothiazide may enhance the anti-hypertensive effect of felodipine.

Fluconazole, hydrochlorothiazide

The co-administration may increase the plasma levels of fluconazole and an adjustment of dose may be needed

Glycyrrhiza, hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalaemia.

Griseofulvin, hydrochlorothiazide

Thiazides may enhance the photosensitizing effects of griseofulvin

Griseofulvin, thiazides

Thiazides may enhance the photosensitizing effects of griseofulvin

Guanethidine, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Halofantrine, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Haloperidol, hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, hydroquinidine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, hypnotics

Increased hypotensive effect.

Hydrochlorothiazide, ibutilide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, ifosfamide

The co-administration of ifosfamide and hydrochlorothiazide may enhance the myelosuppression

Hydrochlorothiazide, imipramine

Increased hypotensive effect.

Hydrochlorothiazide, indometacin

NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics

Hydrochlorothiazide, insulin ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary

Hydrochlorothiazide, iodinated contrast media ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be rehydrated before administration.

Hydrochlorothiazide, irbesartan [2] ---> SmPC of [2] of EMA

In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.

Hydrochlorothiazide, kaliuretic medicines

Hydrochlorothiazide, levomepromazine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, lithium

Renal clearance of lithium is reduced by thiazides, therefore the risk of lithium toxicity may be increased with hydrochlorothiazide. Co-administration of lithium and hydrochlorothiazide is not recommended.

Hydrochlorothiazide, memantin [2] ---> SmPC of [2] of EMA

There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.

Hydrochlorothiazide, metformin ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.

Hydrochlorothiazide, methotrexate ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents and potentiate their myelosuppressive effects.

Hydrochlorothiazide, methyldopa ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa. Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Hydrochlorothiazide, mizolastine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, muscle relaxants (non-depolarizing) ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazides potentiate the action of curare derivatives.

Hydrochlorothiazide, narcotics ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g.by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Hydrochlorothiazide, nebivolol [2] ---> SmPC of [2] of eMC

Co-administration of hydrochlorothiazide did not affect the pharmacokinetics of nebivolol.

Hydrochlorothiazide, neuroleptics

Increase of the hypotensive effect

Hydrochlorothiazide, noradrenaline ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide may reduce the response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

Hydrochlorothiazide, norepinephrine ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide may reduce the response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

Hydrochlorothiazide, NSAID

NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics

Hydrochlorothiazide, opioid analgesics ---> SmPC of [enalapril/hydrochlorothiazide] of eMC

Potentiation of orthostatic hypotension may occur.

Hydrochlorothiazide, oral antidiabetics ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary

Hydrochlorothiazide, organic nitrates

Increased hypotensive effect.

Hydrochlorothiazide, pentamidine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, phenothiazines

Thiazides may enhance the photosensitizing effects of phenothiazines

Hydrochlorothiazide, phenytoin

Phenytoin may decrease the antihypertensive and diuretic effect of hydrochlorothiazide

Hydrochlorothiazide, pimozide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, pregnancy

Hydrochlorothiazid passes the placenta. Its use during the second and third trimester may compromise foeto-placental perfusion

Hydrochlorothiazide, probenecide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Dosage adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid.

Hydrochlorothiazide, prokinetics ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

It is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.

Hydrochlorothiazide, quinidine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, renin inhibitors ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Hydrochlorothiazide, retinoids

Thiazides may enhance the photosensitizing effects of retinoids

Hydrochlorothiazide, salicylates

Salicylate decreases the hypotensive and diuretic effect of hydrochlorothiazide. Hydrochlorothiazide may increase the toxic effect of salicylate on CNS

Hydrochlorothiazide, sotalol ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, sparfloxacin ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, stimulant laxatives

Hydrochlorothiazide, sucroferric oxyhydroxide [2] ---> SmPC of [2] of EMA

In vitro studies did not show any relevant interaction

Hydrochlorothiazide, sulfinpyrazone ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Dosage adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid.

Hydrochlorothiazide, sulfonylureas

Thiazides may enhance the photosensitizing effects of sulfonylureas

Hydrochlorothiazide, sulphonamides

Thiazides may enhance the photosensitizing effects of sulfonamides

Hydrochlorothiazide, sulpiride ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, sultopride ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, symptomatic hyperuricaemia ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Hydrochlorothiazide, systemic lupus erythematosus ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.

Hydrochlorothiazide, telmisartan [2] ---> SmPC of [2] of EMA

Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion and in a risk of hypotension when initiating therapy with telmisartan.

Hydrochlorothiazide, tenoxicam

Decreased hypotensive effect of hydrochlorothiazide.

Hydrochlorothiazide, terfenadine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, teriparatide [2] ---> SmPC of [2] of EMA

FORSTEO has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide. No clinically significant interactions were noted.

Hydrochlorothiazide, tetracyclines

The co-administration may increase the plasma levels of urea. Thiazides may enhance the photosensitizing effects of tetracyclines

Hydrochlorothiazide, thioridazine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, tiapride ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, topiramate [2] ---> SmPC of [2] of eMC

The results of a study indicate that topiramate Cmax increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose.

Hydrochlorothiazide, torsades de pointes inducing drugs ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, tricyclic antidepressant ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Potentiation of orthostatic hypotension may occur.

Hydrochlorothiazide, trifluoperazine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, tubocuranine ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

Thiazides potentiate the action of curare derivatives.

Hydrochlorothiazide, uricosuric agents ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Dosage adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid.

Hydrochlorothiazide, valsartan [2] ---> SmPC of [2] of eMC

In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan and hydrochlorothiazide

Hydrochlorothiazide, vasodilators ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Thiazides potentiate the antihypertensive action of other antihypertensive drugs

Hydrochlorothiazide, vincamine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydrochlorothiazide, vitamin D ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Administration of thiazide diuretics with vitamin D or with calcium salts may potentiate the rise in serum calcium.

Lithium, thiazides ---> SmPC of [hydrochlorothiazide] of EMA

Thiazides decrease the renal clearance of lithium and can increase the risk of lithium toxicity. The combination is not recommended

Retinoids, thiazides

Thiazides may enhance the photosensitizing effects of retinoids

Sulphonamides, thiazides

Thiazides may enhance the photosensitizing effects of sulfonamides

Tetracyclines, thiazides

The co-administration may increase the plasma levels of urea

Hydrocodone

Ability to drive, hydrocodone

Decreased ability to react

Alcohol, hydrocodone

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Anaesthetics, hydrocodone

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Antihistamines, hydrocodone

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Antihypertensives, hydrocodone

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Breast-feeding, hydrocodone

Hydrocodone is contraindicated in breastfeeding

CNS depressants, hydrocodone

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Dasabuvir with ombitasvir/paritaprevir/ritonavir, hydrocodone ---> SmPC of [dasabuvir] of EMA

CYP3A4 inhibition by ritonavir. A reduction of hydrocodone dose by 50% and/or clinical monitoring should be considered when administered with Exviera + ombitasvir/paritaprevir/ritonavir.

Dextromethorphan/quinidine [1], hydrocodone ---> SmPC of [1] of EMA

In the case of pro-drugs whose actions are mediated by the CYP2D6-produced metabolites, efficacy may be substantially reduced by dextromethorphan/quinidine due to inhibition of CYP2D6 and hence impaired formation of the active metabolite.

H2 antagonists, hydrocodone

The co-administration may enhance the hydrocodone effects and increase the respiratory depression

Hydrocodone, hypnotics

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Hydrocodone, IMAOs

The co-administration of hydrocodone mit MAOI and within 2 weeks after MAOI discontinuation is contraindicated

Hydrocodone, neuroleptics

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Hydrocodone, ombitasvir/paritaprevir/ritonavir [2] ---> SmPC of [2] of EMA

Hydrocodone (as given in a fixed-dose hydrocodone/paracetamol). CYP3A4 inhibition by ritonavir. A reduction of hydrocodone dose by 50% and/or clinical monitoring should be considered when administered with Viekirax with or without dasabuvir .

Hydrocodone, opiate agonists

The co-administration may enhance the sedative and respiratory depressor effects

Hydrocodone, pregnancy

Hydrocodone is contraindicated in pregnancy

Hydrocodone, quinidine ---> SmPC of [dextromethorphan/quinidine] of EMA

In the case of pro-drugs whose actions are mediated by the CYP2D6-produced metabolites, efficacy may be substantially reduced by quinidine due to inhibition of CYP2D6 and hence impaired formation of the active metabolite.

Hydrocodone, secretolytics

The cough reflex inhibition may cause secretion congestion

Hydrocodone, sedatives

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Hydrocodone, voriconazole [2] ---> SmPC of [2] of EMA

Dose reduction in oxycodone and other long-acting opiates metabolized by CYP3A4 (e.g., hydrocodone) should be considered. Frequent monitoring for opiate-associated adverse reactions may be necessary.

Hydrocortisone (Plenadren)

Ability to drive, hydrocortisone [2] ---> SmPC of [2] of EMA

Plenadren has minor influence on the ability to drive and use machines. Fatigue and episodes of short-lasting vertigo have been reported. Untreated and poorly replaced adrenal insufficiency may affect the ability to drive and use machines.

Anticholinergics, hydrocortisone

Additional increase in the intraocular pressure

Antidiabetics, hydrocortisone

Decreased hypoglycaemic effect

Atropine, hydrocortisone

Additional increase in the intraocular pressure

Barbiturates, hydrocortisone [2] ---> SmPC of [2] of EMA

Potent CYP 3A4 inducers can enhance the metabolic clearance of cortisol, decrease terminal half-life and thus reduce circulating levels and increase fluctuations of cortisol (due to shorter terminal half-life).

Bleomycin, hydrocortisone

Incompatibility

Breast-feeding, hydrocortisone [2] ---> SmPC of [2] of EMA

Infants of mothers taking high doses of systemic glucocorticoids for prolonged periods may be at risk of adrenal suppression.

Carbamazepine, hydrocortisone [2] ---> SmPC of [2] of EMA

Cardiac glycosides, hydrocortisone

Increased cardiac glycoside effect by hypokaliemia

Chloroquine, hydrocortisone

Increased risk of myopathies and cardiomyopathies

Cholestyramine, hydrocortisone

Cholestyramine decreases the effect of hydrocortisone

Clarithromycin, hydrocortisone [2] ---> SmPC of [2] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Colestipol, hydrocortisone

Colestipol decreases the effect of hydrocortisone

Corticosteroids, mifepristone ---> SmPC of [hydrocortisone] of EMA

The effect of corticosteroids may be reduced for 3-4 days after treatment with mifepristone

Coumarin anticoagulants, hydrocortisone

Decreased anticoagulant effect, an adjustment of dose may be necessary

Cyclosporine, hydrocortisone

Increased plasma concentration of cyclosporine and the risk of cerebral seizures

Efavirenz, hydrocortisone [2] ---> SmPC of [2] of EMA

Erythromycin, hydrocortisone [2] ---> SmPC of [2] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Fertility, hydrocortisone [2] ---> SmPC of [2] of EMA

Patients with adrenal insufficiency have been shown to have reduced parity, which is most likely due to the underlying disease, but there is no indication that hydrocortisone in doses for replacement therapy will affect fertility.

Foods, hydrocortisone

Take with food to reduce irritation.

Gastric emptying, hydrocortisone [2] ---> SmPC of [2] of EMA

The clinical response needs to be monitored in patients given medicinal products affecting gastric emptying and motility

Grapefruit juice, hydrocortisone [2] ---> SmPC of [2] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], itraconazol ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], ketoconazole ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], nevirapine ---> SmPC of [1] of EMA

Hydrocortisone [1], phenytoin ---> SmPC of [1] of EMA

Hydrocortisone [1], posaconazole ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], pregnancy ---> SmPC of [1] of EMA

Untreated adrenal insufficiency during pregnancy is associated with poor outcome of both the mother and the foetus, therefore it is important to continue treatment during pregnancy.

Hydrocortisone [1], primidone ---> SmPC of [1] of EMA

Hydrocortisone [1], rifabutin ---> SmPC of [1] of EMA

Hydrocortisone [1], rifampicin ---> SmPC of [1] of EMA

Hydrocortisone [1], ritonavir ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], St. John's wort ---> SmPC of [1] of EMA

Hydrocortisone [1], strong CYP3A4 inductors ---> SmPC of [1] of EMA

Hydrocortisone [1], strong CYP3A4 inhibitors ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], telithromycin ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone [1], voriconazole ---> SmPC of [1] of EMA

Potent CYP 3A4 inhibitors can inhibit the metabolism of hydrocortisone, and thus increase blood levels.

Hydrocortisone, hydroxychloroquine

Increased risk of myopathies and cardiomyopathies

Hydrocortisone, indometacin

Increased risk of gastrointestinal haemorrhages

Hydrocortisone, lenacapavir [2] ---> SmPC of [2] of EMA

Plasma concentrations of corticosteroids may be increased when co-administered with lenacapavir.

Hydrocortisone, mefloquine

Increased risk of myopathies and cardiomyopathies

Hydrocortisone, muscle relaxants (non-depolarizing)

The combination can result in prolonged muscle relaxation

Hydrocortisone, natriuretic agents

Increased potassium excretion

Hydrocortisone, NSAID

Increased risk of gastrointestinal haemorrhages

Hydrocortisone, praziquantel

The co-administration may decrease the plasma levels of praziquantel

Hydrocortisone, protirelin

Reduction of TSH-increase

Hydrocortisone, salicylates

Increased risk of gastrointestinal haemorrhages

Hydrocortisone, trastuzumab

Trastuzumab may increase the risk of neutropenia and anemia.

CONTRAINDICATIONS of Hydrocortisone (Plenadren)

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

https://www.ema.europa.eu/en/documents/product-information/plenadren-epar-product-information_en.pdf. 11/10/2023

Hydromorphone

Ability to drive, hydromorphone [2] ---> SmPC of [2] of eMC

Hydromorphone may cause drowsiness and patients should not drive or operate machinery if affected.

Alcohol, hydromorphone

Alcohol may potentiate the pharmacodynamic effects of hydromorphone. The concomitant use should be avoided

Breast-feeding, hydromorphone [2] ---> SmPC of [2] of eMC

Hydromorphone is not recommended in the breast-feeding mother as there are insufficient animal or human data to justify such use.

Buprenorphine, hydromorphone

The co-administration may decrease the analgetic effect by competitive blocking of receptors and increase the risk of abstinence syndrome. Combination contraindicated

CNS depressants, hydromorphone [2] ---> SmPC of [2] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

General anesthetics, hydromorphone [2] ---> SmPC of [2] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

Hydromorphone [1], hypnotics ---> SmPC of [1] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

Hydromorphone [1], IMAOs ---> SmPC of [1] of eMC

Concurrent administration of hydromorphone with monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use is contraindicated

Hydromorphone [1], neuroleptics ---> SmPC of [1] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

Hydromorphone [1], opiates ---> SmPC of [1] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

Hydromorphone [1], pregnancy ---> SmPC of [1] of eMC

Hydromorphone is not recommended in pregnancy as there are insufficient animal or human data to justify such use.

Hydromorphone [1], sedatives ---> SmPC of [1] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

Hydromorphone [1], tranquilizers ---> SmPC of [1] of eMC

Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression

Hydromorphone, indocyanine green

Extinction attenuation

Hydromorphone, muscle relaxants

Increased effect of muscle relaxant and of respiratory depression

Hydromorphone, nalbuphine

The co-administration may decrease the analgetic effect by competitive blocking of receptors and increase the risk of abstinence syndrome. Combination contraindicated

Hydromorphone, opioid agonist/antagonists

The co-administration may decrease the analgetic effect by competitive blocking of receptors and increase the risk of abstinence syndrome. Combination contraindicated

Hydromorphone, pentazocine

The co-administration may decrease the analgetic effect by competitive blocking of receptors and increase the risk of abstinence syndrome. Combination contraindicated

CONTRAINDICATIONS of Hydromorphone

- Hydromorphone is contra-indicated in patients with known hypersensitivity to hydromorphone or other ingredients in the formulation.

- It is also contra-indicated in respiratory depression with hypoxia or elevated carbon dioxide levels in the blood,

- pregnancy,

- coma,

- acute abdomen,

- hepatic impairment,

- paralytic ileus,

- concurrent administration of monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use.

- Hydromorphone should be avoided in patients with raised intracranial pressure or head injury, and also in patients with convulsive disorders or acute alcoholism.

http://www.medicines.org.uk/emc/

Hydroquinidine

Ability to drive, hydroquinidine

Depending on the individual patient's response the ability to drive a vehicle or to use machines may be impaired.

Acetazolamide, hydroquinidine

The urinary alkalinizing agent alkalizes the urine and decreases urinary excretion of hydroquinidine and increases plasma levels and overdose risk of hydroquinidine

Aliskiren/hydrochlorothiazide, hydroquinidine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Ambenonium, hydroquinidine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Amiodarone [1], hydroquinidine ---> SmPC of [1] of eMC

The combined therapy of amiodarone with drugs which prolong the QT interval is contra-indicated due to the increased risk of torsades de pointes

Amisulpride, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Amphotericin, hydroquinidine

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Anticholinesterase, hydroquinidine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Bepridil, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Betablockers, hydroquinidine

Alterations of contractility, automatism and conduction (suppression of sympathetic compensatory mechanisms)

Betaxolol, hydroquinidine

The combination may cause alterations of contractibility and stimulus conduction by suppression of sympathetic compensatory mechanisms

Bisoprolol, hydroquinidine

Negative inotropic effect with risk of decompensated cardiac failure (synergistic effects). The co-administration is contraindicated

Breast-feeding, hydroquinidine

Hydroquinidine pass into the breast milk and its use must be avoided during breastfeeding

Carbamazepine, hydroquinidine

Concurrent administration of hydroquinidine with enzyme-inducing drugs may reduce the plasma concentrations of hydroquinidine.

Carteolol, hydroquinidine

The co-administration increases the risk of heart rhythm disorders, particularly torsades de pointes

Carvedilol, hydroquinidine

Negative inotropic effect with risk of decompensated cardiac failure (synergistic effects). The co-administration is contraindicated

Chlorpromazine, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Cisapride, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Class IA antiarrhythmic agents, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Class III antiarrhythmic agents, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Clonidine, hydroquinidine

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Cyamemazine, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Delamanid [1], hydroquinidine ---> SmPC of [1] of EMA

Deslanoside, hydroquinidine

Digoxine (and by extrapolation deslanoside). There is increased digoxinemia due to decreased renal clearance of digoxin. There is also rhythm disorders (excessive bradycardia and AV conduction disorders)

Digital glycosides, hydroquinidine

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Digoxin, hydroquinidine

Diltiazem, hydroquinidine

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Diphemanil, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Disopyramide, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Dofetilide, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Donepezil, hydroquinidine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Droperidol, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Drugs inducing bradycardia, hydroquinidine

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Enzyme inductors, hydroquinidine

Concurrent administration of hydroquinidine with enzyme-inducing drugs may reduce the plasma concentrations of hydroquinidine.

Erythromycin, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Galantamine, hydroquinidine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Glucocorticoids, hydroquinidine

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Guanfacin, hydroquinidine

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Halofantrine, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Haloperidol, hydroquinidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydrochlorothiazide, hydroquinidine ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Hydroquinidine, hypokalemia

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, ibutilide

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, itraconazol

Concomitant use may cause hearing impairment and chinchonism due to itraconazol decreases the hepatic metabolism of hydroquinidine

Hydroquinidine, levomepromazine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with torsades de pointes-inducing medicinal products

Hydroquinidine, mefloquine

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, mequitazine

Concomitant use of mequitazine with drugs that prolong the QT interval is contraindicated

Hydroquinidine, metoprolol

Negative inotropic effect with risk of decompensated cardiac failure (synergistic effects). The co-administration is contraindicated

Hydroquinidine, mizolastine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, moxifloxacin [2] ---> SmPC of [2] of eMC

Hydroquinidine, nadolol [2] ---> SmPC of [2] of eMC

Additive or antagonistic effects may occur with nadolol and antiarrhythmic agents.

Hydroquinidine, negative inotropic drugs

The combination of hydroquinidine and drugs with negative inotrope and/or bradycardic effect and/or slow AV conduction should be done with close observation and ECG monitoring

Hydroquinidine, neostigmine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Hydroquinidine, non-potassium-sparing diuretics

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, pentamidine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, phenobarbital

Concurrent administration of hydroquinidine with enzyme-inducing drugs may reduce the plasma concentrations of hydroquinidine.

Hydroquinidine, phenytoin

Concurrent administration of hydroquinidine with enzyme-inducing drugs may reduce the plasma concentrations of hydroquinidine.

Hydroquinidine, pimozide

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, piperaquine/artenimol [2] ---> SmPC of [2] of EMA

The combination of piperaquine/dihydroartemisinin with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval

Hydroquinidine, pregnancy

Hydroquinidine is not recommended for use during pregnancy

Hydroquinidine, primidone

Concurrent administration of hydroquinidine with enzyme-inducing drugs may reduce the plasma concentrations of hydroquinidine.

Hydroquinidine, pyridostigmine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Hydroquinidine, quinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, rifampicin

Concurrent administration of hydroquinidine with enzyme-inducing drugs may reduce the plasma concentrations of hydroquinidine.

Hydroquinidine, rivastigmine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Hydroquinidine, saquinavir/ritonavir ---> SmPC of [saquinavir] of EMA

The combination is contraindicated due to the potential for life threatening cardiac arrhythmia

Hydroquinidine, sodium bicarbonate

The urinary alkalinizing agent alkalizes the urine and decreases urinary excretion of hydroquinidine and increases plasma levels and overdose risk of hydroquinidine

Hydroquinidine, sotalol [2] ---> SmPC of [2] of eMC

Sotalol should be given with extreme caution in conjunction with other drugs known to prolong the QT-interval. Drugs that prolong the QT-interval may cause torsades de pointes. The co-administration with sotalol is contraindicated

Hydroquinidine, spiramycin

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, stimulant laxatives

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, sulpiride

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, sultopride

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, tacrine

Risk excessive bradycardia due to the bradycardic effects of both active ingredients may be additive

Hydroquinidine, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Hydroquinidine, tetracosactide

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, thioridazine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, tiapride

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, toremifene [2] ---> SmPC of [2] of EMA

Hydroquinidine, torsades de pointes inducing drugs

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, trifluoperazine

Concomitant use is not recommended due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, trometamol

The urinary alkalinizing agent alkalizes the urine and decreases urinary excretion of hydroquinidine and increases plasma levels and overdose risk of hydroquinidine

Hydroquinidine, urinary alkalinizing agents

The urinary alkalinizing agent alkalizes the urine and decreases urinary excretion of hydroquinidine and increases plasma levels and overdose risk of hydroquinidine

Hydroquinidine, verapamil

Concomitant use of hydroquinidine and bradycardiac agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, vincamine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Hydroquinidine, xipamide

The combination increases the risk of ventricular arrhythmias, particularly torsades de pointes (favored by hypokaliemia). It is recommended a special caution

Hydrotalcite

Aluminium hydroxide, fruit juice

The intake of acid beverages (e. g. fruit juices, wine) together with aluminium-containing antacids increases the intestinal absorption of aluminium

Aluminium hydroxide, juices

The intake of acid beverages (e. g. fruit juices, wine) together with aluminium-containing antacids increases the intestinal absorption of aluminium

Anionic drugs, hydrotalcite

Hydrotalcite, urinary alkalinizing agent, may increase the renal elimination of the acid (anionic) medicinal products (e.g. salicylates)

Anticholinergics, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Breast-feeding, hydrotalcite

Strict indication

Carbenoxolone, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Cardiac glycosides, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Cationic drugs, hydrotalcite

Hydrotalcite, urinary alkalinizing agent, may decrease the renal elimination of the basic (cationic) medicinal products (e.g. quinidine)

Chenodeoxycholic acid, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Cimetidine, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Ciprofloxacin, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Coumarin anticoagulants, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Digoxin, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Fluoroquinolones, hydrotalcite

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, iron

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, isoniazid

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, juices

The concomitant use (should be avoided) of fruit juices and hydrotalcite increases the intestinal absorption of aluminium.

Hydrotalcite, ketoconazole

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, mecamylamine

Hydrotalcite should not be coadministered with mecamylamine due to hydrotalcite may decrease the efficacy of mecamylamine

Hydrotalcite, methenamine

Hydrotalcite should not be coadministered with methenamine due to hydrotalcite may decrease the efficacy of methenamine

Hydrotalcite, norfloxacin

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, ofloxacin

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, phenobarbital

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant women

Hydrotalcite, prulifloxacin

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, quinidine

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, salicylates

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, sodium fluoride

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, tetracyclines

The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours

Hydrotalcite, wine

The concomitant use (should be avoided) of wine and hydrotalcite increases the intestinal absorption of aluminium.

CONTRAINDICATIONS of Hydrotalcite

None known

http://www.medicines.org.uk/emc/

Hydroxocobalamine (Cyanokit)

Breast-feeding, hydroxocobalamine [2] ---> SmPC of [2] of EMA

Because hydroxocobalamin will be administered in potentially life-threatening situations, feeding is not a contraindication to its use.

Hydroxocobalamine [1], pregnancy ---> SmPC of [1] of EMA

There are no adequate data from the use of hydroxocobalamin in pregnant women and the potential risk for humans is unknown.

CONTRAINDICATIONS of Hydroxocobalamine (Cyanokit)

- None.

https://www.ema.europa.eu/en/documents/product-information/cyanokit-epar-product-information_en.pdf 16/12/2025

Other trade names: Megamilbedoce, Hidroxocobalamina (cloruro) Genfarma,

Hydroxycarbamide (Siklos)

Ability to drive, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Siklos has minor influence on the ability to drive and use machines. Patients should be advised not to drive or operate machines, if dizziness is experienced while taking Siklos.

Antiretrovirals, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Potentially fatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxycarbamide in combination with antiretroviral medicinal products, particularly didanosine plus stavudine.

Breast-feeding, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Hydroxycarbamide is excreted in human milk. Because of the potential for serious adverse reactions in infants, breastfeeding must be discontinued while taking Siklos.

Cytosine arabinoside, hydroxycarbamide

Hydroxycarbamide increases the cytotoxicity of cytosine arabinoside

Didanosine/stavudine, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Fertility, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Fertility in males might be affected by treatment. Very common reversible oligo-and azoospermia have been observed in man, although these disorders are also associated with the underlying disease.

Fluoropyrimidines, hydroxycarbamide

Hydroxycarbamide increases the cytotoxicity of fluoropyrimidine

Foods, hydroxycarbamide [2] ---> SmPC of [2] of EMA

Conforming to the individual prescribed dose, the tablet or the half or quarter of the tablet should be taken once daily, preferably in the morning before breakfast and, when necessary, with a glass of water or a very small amount of food.

Hydroxycarbamide [1], men ---> SmPC of [1] of EMA

Male and female patients on hydroxycarbamide wishing to conceive should stop treatment 3 to 6 months before pregnancy if possible.

Hydroxycarbamide [1], myelosuppressive agents ---> SmPC of [1] of EMA

Concurrent use of hydroxycarbamide and other myelosuppressive medicinal products/radiation therapy may increase bone marrow depression, GI disturbances or mucositis. An erythema caused by radiation therapy may be aggravated by hydroxycarbamide.

Hydroxycarbamide [1], pregnancy ---> SmPC of [1] of EMA

Patients on hydroxycarbamide should be made aware of the risks to the foetus. There is limited amount of data from the use of hydroxycarbamide in pregnant women. Siklos is not recommended during pregnancy.

Hydroxycarbamide [1], pregnancy ---> SmPC of [1] of EMA

The patient should be instructed to immediately contact a doctor in case of suspected pregnancy.

Hydroxycarbamide [1], radiotherapy ---> SmPC of [1] of EMA

Hydroxycarbamide [1], vaccinations with live organism vaccines ---> SmPC of [1] of EMA

The patient's antibody response to vaccines may be decreased. Treatment with Siklos and concomitant immunisation with live virus vaccines should only be performed if benefits clearly outweigh potential risks.

Hydroxycarbamide [1], women of childbearing potential ---> SmPC of [1] of EMA

Women of childbearing age receiving hydroxycarbamide should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.

Hydroxycarbamide [1], women of childbearing potential ---> SmPC of [1] of EMA

An effective method of contraception is strongly recommended in women of childbearing potential.

Hydroxycarbamide, voxelotor [2] ---> SmPC of [2] of EMA

Itraconazole (a strong CYP3A4 inhibitor), omeprazole (acid reducing agent), and hydroxycarbamide had no effect on the pharmacokinetics of voxelotor.

CONTRAINDICATIONS of Hydroxycarbamide (Siklos)

- Hypersensitivity to the active substance or to any of the excipients.

- Severe hepatic impairment (Child-Pugh classification C).

- Severe renal impairment (creatinine clearance < 30 ml/min).

- Toxic ranges of myelosuppression as described in section 4.2.

- Breast-feeding

https://www.ema.europa.eu/en/documents/product-information/siklos-epar-product-information_en.pdf 24/11/2025

Other trade names: Hydrea, Xromi,

Hydroxychloroquine

Ability to drive, hydroxychloroquine [2] ---> SmPC of [2] of eMC

Impaired visual accommodation soon after the start of treatment has been reported and patients should be warned regarding driving or operating machinery.

Agalsidase, hydroxychloroquine

The combination should be avoided due to hydroxychloroquine inhibits the intra-cellular alfa-galactosidase activity

Aminoglycoside antibiotics, hydroxychloroquine [2] ---> SmPC of [2] of eMC

The aminoglycoside antibiotic may enhance the direct blocking action of the hydroxychloroquine at the neuromuscular junction

Amiodarone, hydroxychloroquine

Concomitant use of hydroxychloroquine and arrhytmogenic agents may increase the risk of cardiac arrhythmias

Ampicillin, hydroxychloroquine

Decreased absorption of ampicillin

Antacids, hydroxychloroquine [2] ---> SmPC of [2] of eMC

Antacids may reduce absorption of hydroxychloroquine so it is advised that a 4 hour interval be observed between hydroxychloroquine and antacid dosaging.

Antirabic vaccine [1], hydroxychloroquine ---> SmPC of [1] of eMC

Hydroxychloroquine may decrease the antibody response to primary immunisation with intradermal human diploid-cell rabies vaccine.

Arrhytmogenic agents, hydroxychloroquine

Concomitant use of hydroxychloroquine and arrhytmogenic agents may increase the risk of cardiac arrhythmias

Artemether/lumefantrine, hydroxychloroquine

The coadministration should be avoided

Betablockers, hydroxychloroquine

Hydroxychloroquine may decrease the metabolism of some betablockers

Breast-feeding, hydroxychloroquine [2] ---> SmPC of [2] of eMC

Careful consideration should be given to using hydroxychloroquine during lactation, since it has been shown to be excreted in small amounts in human breast milk

Cimetidine, hydroxychloroquine [2] ---> SmPC of [2] of eMC

The inhibition of hydroxychloroquine metabolism by cimetidine may increase plasma concentration of the antimalarial

Cloprednol, hydroxychloroquine

Increased risk of myopathies and cardiomyopathies

Corticosteroids, hydroxychloroquine

Concomitant use of hydroxychloroquine and corticosteroids may enhance myopathies or cardiomyopathies

Dapsone, hydroxychloroquine

The combination may increase the risk of hemolytic reactions.

Deflazacort, hydroxychloroquine

The co-administration of hydroxychloroquine and corticoids may increase the risk of myopathies and cardiomyopathies

Digoxin, hydroxychloroquine [2] ---> SmPC of [2] of eMC

Hydroxychloroquine may increase the plasma concentrations of digoxin.

Ethosuximide, hydroxychloroquine

Concomitant use of antiepileptic and antimalarial agents may increase the risk of seizures

Folic acid antagonists, hydroxychloroquine

Increased effect of folic acid antagonist

Foods, hydroxychloroquine

Each dose should be taken with a meal or glass of milk.

Halofantrine, hydroxychloroquine

Halofantrine prolongs the QT interval and should not be used together with other drugs that may induce cardiac arrhythmias

Hepatotoxic drugs, hydroxychloroquine

Hydroxychloroquine should not be taken with hepatotoxic agents

Hydrocortisone, hydroxychloroquine

Increased risk of myopathies and cardiomyopathies

Hydroxychloroquine [1], insulin ---> SmPC of [1] of eMC

As hydroxychloroquine may enhance the effects of a hypoglycaemic treatment, a decrease in doses of insulin or antidiabetic drugs may be required.

Hydroxychloroquine [1], kaolin ---> SmPC of [1] of eMC

Antacids may reduce absorption of hydroxychloroquine so it is advised that a 4 hour interval be observed between hydroxychloroquine and antacid dosaging.

Hydroxychloroquine [1], neostigmine ---> SmPC of [1] of eMC

Hydroxychloroquine may antagonise of effect of neostigmine

Hydroxychloroquine [1], oral antidiabetics ---> SmPC of [1] of eMC

As hydroxychloroquine may enhance the effects of a hypoglycaemic treatment, a decrease in doses of insulin or antidiabetic drugs may be required.

Hydroxychloroquine [1], pregnancy ---> SmPC of [1] of eMC

Hydroxychloroquine crosses the placenta. It should not be used in pregnancy.

Hydroxychloroquine [1], pyridostigmine ---> SmPC of [1] of eMC

Hydroxychloroquine may antagonise of effect of pyridostigmine

Hydroxychloroquine, IMAOs

Hydroxychloroquine should not be taken with monoamine oxidase inhibitors

Hydroxychloroquine, indometacin

Increased risk of sensibilization and retinopathy

Hydroxychloroquine, lanthanum carbonate [2] ---> SmPC of [2] of eMC

The lanthanum carbonate decreases the absorption of hydroxychloroquine. Separate administration by at least 2 hours

Hydroxychloroquine, mefloquine

Mefloquine may increase the risk of seizures

Hydroxychloroquine, methotrexate [2] ---> SmPC of [2] of EMA

A rise in the toxicity of methotrexate is generally not anticipated when methotrexate is used concomitantly with other antirheumatic agents (e.g. gold compounds, penicillamine, hydroxychloroquine, sulfasalazine, azathioprine, cyclosporin).

Hydroxychloroquine, methylprednisolone

Increased risk of myopathies and cardiomyopathies

Hydroxychloroquine, metoprolol [2] ---> SmPC of [2] of eMC

Enzyme inhibitors may increase plasma concentrations of hepatically metabolised beta-blockers.

Hydroxychloroquine, metronidazole

Acute dystonic reaction

Hydroxychloroquine, moxifloxacin

Concomitant use of hydroxychloroquine and arrhytmogenic agents may increase the risk of cardiac arrhythmias

Hydroxychloroquine, natalizumab

Hydroxychloroquine may increase the toxicity of natalizumab, especially the risk of infection

Hydroxychloroquine, penicillamine

Penicillamine may increase the risk of severe hematologic, renal adverse reactions and skin reactions

Hydroxychloroquine, phenothiazines

Hydroxychloroquine may increase plasma concentrations of phenothiazines

Hydroxychloroquine, phenylbutazone

Increased risk of exfoliative dermatitis

Hydroxychloroquine, pimecrolimus

Pimecrolimus may enhance the adverse reactions of hydroxychloroquine

Hydroxychloroquine, praziquantel

The co-administration may decrease the plasma levels of praziquantel

Hydroxychloroquine, prednisolone

Increased risk of myopathies and cardiomyopathies

Hydroxychloroquine, prednisone [2] ---> SmPC of [2] of eMC

There is an increased risk of occurrence of myopathies, cardiomyopathies.

Hydroxychloroquine, probenecide

Increased risk of sensibilization and retinopathy

Hydroxychloroquine, seizure-threshold lowering drugs

The co-administration of drugs that may decrease the seizure threshold may increase the risk of seizures

Hydroxychloroquine, sonidegib [2] ---> SmPC of [2] of EMA

Patients should be closely monitored for muscle-related symptoms if Odomzo is used in combination with certain medicinal products that may increase the potential risk of developing muscle toxicity

Hydroxychloroquine, tacrolimus

Tacrolimus (topical) may enhance the adverse reactions of hydroxychloroquine. Hydroxychloroquine with systemic tacrolimus may enhance the effect of QTc interval prolongation

Hydroxychloroquine, trastuzumab

Concomitant use of hydroxychloroquine y trastuzumab may increase the risk of neutropenia

Hydroxychloroquine, triamcinolone

Increased risk of myopathies and cardiomyopathies

Hydroxychloroquine, triamcinolone acetonide

Increased risk of myopathies and cardiomyopathies

Hydroxychloroquine, vaccinations

The immunosuppressive effect of hydroxychloroquine may decrease the therapeutic efficacy of inactivated vaccinations

Hydroxychloroquine, vaccinations with live organism vaccines

Decrease of the immune response to live attenuated virus vaccines and increased risk of infections for a period of 3 months

CONTRAINDICATIONS of Hydroxychloroquine

- known hypersensitivity to 4-aminoquinoline compounds

- pre-existing maculopathy of the eye

- pregnancy

http://www.medicines.org.uk/emc/

Hydroxyzine

Ability to drive, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may impair their ability to perform activities requiring mental alertness or physical co-ordination such as operating machinery or driving a vehicle.

Adrenaline, hydroxyzine [2] ---> SmPC of [2] of eMC

Hydroxyzine has been shown to inhibit and reverse the vasopressor effect of adrenaline

Alcohol dehydrogenase inhibitors, hydroxyzine

The inhibition of alcohol dehydrogenase may increase the plasma levels of hydroxycine

Alcohol, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may enhance their response to alcohol

Amiodarone, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Anticholinergics, hydroxyzine [2] ---> SmPC of [2] of eMC

Additive anticholinergic effects may occur if hydroxyzine is administered concomitantly with other anticholinergic agents

Anticholinesterase, hydroxyzine [2] ---> SmPC of [2] of eMC

Hydroxyzine may antagonise the effects of anticholinesterase drugs

Antiemetics, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may enhance their response to antiemetics

Antihypertensives, hydroxyzine

The co-administration of antihypertensive agents with hydroxyzine may cause enhanced sedation

Antimuscarinic agents, hydroxyzine [2] ---> SmPC of [2] of eMC

Antimuscarinic side effects (both peripheral and central) may be increased if hydroxyzine is given with antimuscarinics

Barbiturates, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may enhance their response to barbiturates

Benzylpenicillin, hydroxyzine

Incompatible with benzylpenicillin in solution

Betahistine, hydroxyzine [2] ---> SmPC of [2] of eMC

Hydroxyzine may antagonise the effects of betahistine

Breast-feeding, hydroxyzine [2] ---> SmPC of [2] of eMC

Hydroxyzine should not be given to nursing mothers

Cimetidine, hydroxyzine [2] ---> SmPC of [2] of eMC

Cimetidine has been shown to increase the serum concentrations of hydroxyzine and to decrease peak concentrations of the metabolite cetirizine

Citalopram, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Class IA antiarrhythmic agents, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Class III antiarrhythmic agents, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

CNS depressants, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may enhance their response to other CNS depressants

Disopyramide, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Drugs inducing bradycardia, hydroxyzine

Caution is recommended with bradycardia and hypopotassemia inducing medicinal products

Drugs primarily metabolised by CYP2D6, hydroxyzine [2] ---> SmPC of [2] of eMC

Hydroxyzine is an inhibitor of CYP2D6 and may cause drug-drug interactions with CYP2D6 substrates.

Epinephrine, hydroxyzine [2] ---> SmPC of [2] of eMC

Hydroxyzine has been shown to inhibit and reverse the vasopressor effect of adrenaline

Erythromycin, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Escitalopram, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Fluoxetine, hydroxyzine

Hydroxyzine is an inhibitor of CYP2D6 and may cause drug-drug interactions with CYP2D6 substrates.

Haloperidol, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], levofloxacin ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], mefloquine ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], methadone ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], moxifloxacin ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], muscle relaxants ---> SmPC of [1] of eMC

Patients should be warned that hydroxyzine may enhance their response to skeletal muscle relaxants

Hydroxyzine [1], neuroleptics ---> SmPC of [1] of eMC

Patients should be warned that hydroxyzine may enhance their response to neuroleptic agents

Hydroxyzine [1], pentamidine ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], pregnancy ---> SmPC of [1] of eMC

Hydroxyzine should not be used during pregnancy

Hydroxyzine [1], prucalopride ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], QT interval prolonging drugs ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], quinidine ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], sotalol ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], toremifene ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], torsades de pointes inducing drugs ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine [1], vandetanib ---> SmPC of [1] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Hydroxyzine, hypokalemia

Caution is recommended with bradycardia and hypopotassemia inducing medicinal products

Hydroxyzine, IMAOs

Enhancement of anticholinergic effect, hypotension, CNS depression, respiratory function depression. The co-administration is contraindicated

Hydroxyzine, phenytoin

Hydroxyzine may antagonise the anticonvulsivant effect of phenytoin

Hydroxyzine, strong CYP3A4 inhibitors

The strong inhibition of CYP3A4 may increase the plasma levels of hydroxycine

CONTRAINDICATIONS of Hydroxyzine

Atarax is contra-indicated in the following:

- patients who have shown previous hypersensitivity to hydroxyzine hydrochloride, cetirizine, other piperazine derivatives, aminophylline or ethylenediamine, or any of the excipients

- asthmatics who have previously experienced a serious anti-histamine-induced adverse bronchopulmonary effect

- porphyria

- pregnancy and breast-feeding

Contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine.

http://www.medicines.org.uk/emc/

Page updated

Google Sites

Report abuse